Voyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on Monday

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $13.55 million for the quarter.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million during the quarter, compared to analysts' expectations of $16.58 million. During the same quarter in the previous year, the company earned $1.25 EPS. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Trading Up 2.5 %

NASDAQ VYGR opened at $3.64 on Monday. The company has a market capitalization of $201.34 million, a PE ratio of 5.13 and a beta of 0.95. Voyager Therapeutics has a 1-year low of $2.75 and a 1-year high of $9.55. The firm's fifty day simple moving average is $3.59 and its 200-day simple moving average is $5.04.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group dropped their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $13.97.

Insider Activity

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.53% of the stock is currently owned by company insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.